O’Harte, F.; Parthsarathy, V.; Craig, S.; Palmer, E.; Irwin, N.
Peptide Co-Agonists for Combined Activation of the APJ and GLP-1 Receptors with Insulinotropic and Satiety Actions Show Potential for Alleviation of Metabolic Dysfunction in Type 2 Diabetes. Med. Sci. Forum 2023, 23, 1.
https://doi.org/10.3390/msf2023023001
AMA Style
O’Harte F, Parthsarathy V, Craig S, Palmer E, Irwin N.
Peptide Co-Agonists for Combined Activation of the APJ and GLP-1 Receptors with Insulinotropic and Satiety Actions Show Potential for Alleviation of Metabolic Dysfunction in Type 2 Diabetes. Medical Sciences Forum. 2023; 23(1):1.
https://doi.org/10.3390/msf2023023001
Chicago/Turabian Style
O’Harte, Finbarr, Vadivel Parthsarathy, Sarah Craig, Ethan Palmer, and Nigel Irwin.
2023. "Peptide Co-Agonists for Combined Activation of the APJ and GLP-1 Receptors with Insulinotropic and Satiety Actions Show Potential for Alleviation of Metabolic Dysfunction in Type 2 Diabetes" Medical Sciences Forum 23, no. 1: 1.
https://doi.org/10.3390/msf2023023001
APA Style
O’Harte, F., Parthsarathy, V., Craig, S., Palmer, E., & Irwin, N.
(2023). Peptide Co-Agonists for Combined Activation of the APJ and GLP-1 Receptors with Insulinotropic and Satiety Actions Show Potential for Alleviation of Metabolic Dysfunction in Type 2 Diabetes. Medical Sciences Forum, 23(1), 1.
https://doi.org/10.3390/msf2023023001
